Everest Medicines’ Nefecon NDA for IgAN Accepted for Review in South Korea
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the New Drug Application...
Auto-immune
Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus
Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...
Everest Medicines’ Nefecon for IgAN Receives NMPA Approval in China
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that its New Drug Application...
RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete...
Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen
Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...
AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management
US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group...
Janssen Presents Real-World Data on Tremfya’s Efficacy in Treatment-Resistant Psoriatic Arthritis
Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical unit, Janssen, has presented real-world efficacy data for...
Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of...
Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US
Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I...
AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues
AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year...
Everest Medicines’ Nefecon Receives First Regional NDA Approval in Macau for IgAN Treatment
China-based Everest Medicines (HKG: 1952) has announced that its New Drug Application (NDA) for Nefecon,...
Eli Lilly’s Omvoh Receives FDA Approval for Ulcerative Colitis Treatment
The US Food and Drug Administration (FDA) has granted regulatory approval to Eli Lilly (NYSE:...
AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment
AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at...
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since...
BMS’s Sotyktu Receives NMPA Approval for Psoriasis Treatment
The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers...
Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA
Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...
Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...
AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study
AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the...
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...
Bio-Thera Solutions’ BAT1806 Receives US FDA Approval as Biosimilar to Actemra/RoActemra
Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, announced that its biosimilar version of...